Aptamers : the new frontier in drug development?
Often called chemical antibodies, aptamers are poised to take on the monoclonal antibodies in therapeutics, diagnostics, and drug development. Stability, low toxicity and immunogenicity, and, perhaps, a higher safety profile - not to mention low-cost advantages - are drawing the attention of big pharma and biotech.
Bob
B
Carlson